跳至主要内容
临床试验/NCT01543945
NCT01543945已完成2 期

Prevention Post Operative Nausea Vomiting in Ambulatory Gynecologic Laparoscopy

Prince of Songkla University1 个研究点 分布在 1 个国家目标入组 340 人开始时间: 2008年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
340
试验地点
1
主要终点
Incidence of PONV in ambulatory gynecologic laparoscopy

研究概览

简要总结

The purpose of this study is to compare the incidence of Postoperative nausea and vomiting between the intervention group who received multimodal antiemetic management and the control group who did not get this protocol.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Ambulatory gynecologic laparoscopy
  • Age 18-45 years
  • ASA class 1-2

排除标准

  • The patients who take opioid, steroid, pyschotics or antiemetic drug within 24 hours before surgery
  • History of antiemetic, anesthetic and analgesic drugs allergy
  • Pregnancy or breast feeding
  • Body mass index >34 kg/square metre

研究组 & 干预措施

Multimodal antiemetic management group

Experimental

Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg

干预措施: Dexamethasone (Drug)

Multimodal antiemetic management group

Experimental

Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg

干预措施: Ondansetron (Drug)

Multimodal antiemetic management group

Experimental

Multimodal antiemetic group : Low risk :no PONV prophylaxis moderate risk : ondansetron 4 mg iv high risk : dexamethasone 4 mg + ondansetron 4 mg Extremely high risk : dexamethasone 4 mg + ondansetron 4 mg + dimenhydrinate 1 mg

干预措施: Dimenhydrinate (Drug)

Control group

Active Comparator

Control group: Low and moderate risk : no PONV prophylaxis High risk : Ondansetron 4 mg. iv Extremely high risk : Ondansetron 4 mg .iv

干预措施: Ondansetron (Drug)

结局指标

主要结局

Incidence of PONV in ambulatory gynecologic laparoscopy

时间窗: four year

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Thanyamon Asampinwat

Assistant Professor

Prince of Songkla University

研究点 (1)

Loading locations...

相似试验